Announced
Synopsis
Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, agreed to merge with Trawsfynydd Therapeutics, a privately-held biotechnology company developing next-generation antivirals for influenza, COVID and other infectious diseases. Financial terms were not disclosed. ”Trawsfynydd has a differentiated pipeline and an accomplished leadership team poised to advance their lead programs. With a shared focus on developing best-in-class medicines for patients with unmet needs, we look forward to Traws’ continued progress with its anti-viral programs and narazaciclib,” Steven Fruchtman, President and CEO Onconova.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.